Longboard Pharmaceuticals
Clinical trials sponsored by Longboard Pharmaceuticals, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Hard-to-Treat seizures: phase 3 trial launches Results expected Oct 2026 (estimated)
- New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency Results expected Dec 2026 (estimated)
-
New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency
Disease control OngoingThis study tests whether the drug LP352 can safely reduce seizures in children and adults with Dravet syndrome, a severe form of epilepsy. About 160 participants will receive either LP352 or a placebo, and researchers will track changes in seizure frequency over several months. T…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Disease control OngoingThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug LP352 aims to control seizures in severe epilepsy over the long term
Disease control By invitation onlyThis phase 3 study is testing the long-term safety and effectiveness of LP352 (Bexicaserin) in 324 children and adults with developmental and epileptic encephalopathy (DEE), including Dravet and Lennox-Gastaut syndromes. Participants who completed earlier studies will receive LP3…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC